Canaccord analyst Richard Close raised the firm’s price target on AdaptHealth (AHCO) to $14 from $13 and keeps a Buy rating on the shares. The firm said 4Q was a step forward in rebuilding investor confidence for Adapt as results showed revenue upside and 2025 guidance that has revenue and adj-EBITDA ranges bracketing both Canaccord and consensus prior estimates, and a respectable FCF range of $180-$220 million.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO: